<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1506210791
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Averaz
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AZACITIDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous, Subcutaneous
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1041.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSN LABORATORIES PRIVATE LIMITED " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSN LABORATORIES PRIVATE LIMITED 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QL01BC07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Averaz is</strong></p><p>Averaz is an anti-cancer agent which belongs to a group of medicines called &lsquo;anti-metabolites&rsquo;. Averaz</p><p>contains the active substance &lsquo;azacitidine&rsquo;.</p><p>&nbsp;</p><p><strong>What Averaz is used for</strong></p><p>Averaz is used in adults who are not able to have a stem cell transplantation to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; higher-risk myelodysplastic syndromes (MDS).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic myelomonocytic leukaemia (CMML).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute myeloid leukaemia (AML).</p><p>&nbsp;</p><p>These are diseases which affect the bone marrow and can cause problems with normal blood cell</p><p>production.</p><p>&nbsp;</p><p><strong>How Averaz works</strong></p><p>Averaz works by preventing cancer cells from growing. Azacitidine becomes incorporated into the</p><p>genetic material of cells (ribonucleic acid (RNA) and deoxyribonucleic acid (DNA)). It is thought to work by altering the way the cell turns genes on and off and also by interfering with the production of new RNA and DNA. These actions are thought to correct problems with the maturation and growth of young blood cells in the bone marrow that cause myelodysplastic disorders, and to kill cancerous cells in leukaemia.</p><p>Talk to your doctor or nurse if you have any questions about how Averaz works or why this medicine has been prescribed for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Averaz</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to azacitidine or any of the other ingredients of this medicine (listed in</p><p>section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have advanced liver cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using Averaz:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have decreased counts of platelets, red or white blood cells.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had a heart condition or heart attack or any history of lung disease.</p><p>&nbsp;</p><p><u>Blood test</u></p><p>You will have blood tests before you begin treatment with Averaz and at the start of each period of</p><p>treatment (called a &lsquo;cycle&rsquo;). This is to check that you have enough blood cells and that your liver and kidneys are working properly.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Averaz is not recommended for use in children and adolescents below the age of 18.</p><p>&nbsp;</p><p><strong>Other medicines and Averaz</strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p>This is because Averaz may affect the way some other medicines work. Also, some other medicines</p><p>may affect the way Averaz works.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><strong>&nbsp;</strong></p><p><u>Pregnancy</u></p><p>You should not use Averaz during pregnancy as it may be harmful to the baby.</p><p>Use an effective method of contraception during and up to 3 months after treatment.</p><p>Tell your doctor straight away if you become pregnant during treatment.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask</p><p>your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>You should not breast-feed when using Averaz. It is not known if this medicine passes into</p><p>human milk.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Men should not father a child while receiving treatment with Averaz. Use an effective method of</p><p>contraception during and up to 3 months after treatment with this medicine.</p><p>&nbsp;</p><p>Talk to your doctor if you wish to conserve your sperm before starting this treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Do not drive or use any tools or machines if you experience side effects, such as tiredness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Before giving you Averaz, your doctor will give you another medicine to prevent nausea and vomiting at the start of each treatment cycle.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 75 mg per m2 body surface area. Your doctor will decide your dose of this medicine, depending on your general condition, height and weight. Your doctor willcheck your progress and may change your dose if necessary.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Averaz is given every day for one week, followed by a rest period of 3 weeks. This &ldquo;treatment cycle&rdquo; will be repeated every 4 weeks. You will usually receive at least 6 treatment cycles.</p><p>&nbsp;</p><p>This medicine will be given to you as an injection under the skin (subcutaneously) by a doctor or</p><p>nurse. It may be given under the skin on your thigh, tummy or upper arm.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your doctor straight away if you notice any of the following side effects:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Drowsiness, shaking, jaundice, abdominal bloating and easy bruising</strong>. These may be</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms of liver failure and can be life-threatening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Swelling of the legs and feet, back pain, reduced passing of water, increased thirst, rapid</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>pulse, dizziness and nausea, vomiting or reduced appetite and feelings of confusion,</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>restlessness or fatigue. </strong>These may be symptoms of kidney failure and can be life-threatening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>A fever</strong>. This could be due to an infection as a result of having low levels of white blood cells,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; which can be life-threatening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Chest pain or shortness of breath which may be accompanied with a fever. </strong>This may be due</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to an infection of the lung called &ldquo;pneumonia&rdquo; and can be life-threatening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Bleeding. </strong>Such as blood in the stools due to bleeding in the stomach or gut, or such as bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inside your head. These may be symptoms of having low levels of platelets in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Difficulty breathing, swelling of the lips, itching or rash. </strong>This may be due to an allergic</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (hypersensitivity) reaction.</p><p>&nbsp;</p><p>Other side effects include:</p><p>&nbsp;</p><p><strong>Very common side effects </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced red blood count (anaemia). You may feel tired and pale.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced white blood cell count. This may be accompanied by a fever. You are also more likely</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to get infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A low blood platelet count (thrombocytopenia). You are more prone to bleeding and bruising.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation, diarrhoea, nausea, vomiting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain, being short of breath.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness (fatigue).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site reaction including redness, pain or a skin reaction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint aches.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red or purple spots under your skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in your belly (abdominal pain).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore nose and throat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Having trouble sleeping (insomnia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nosebleeds (epistaxis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle aches.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness (asthenia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low levels of potassium in your blood.</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding inside your head.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An infection of the blood caused by bacteria (sepsis). This may be due to low levels of white</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cells in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone marrow failure. This can cause low levels of red and white blood cells and platelets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A type of anaemia where your red and white blood cells and platelets are reduced.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An infection in your urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A viral infection causing cold sores (herpes).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding gums, bleeding in the stomach or gut, bleeding from around your back passage due to</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; piles (haemorrhoidal haemorrhage), bleeding in your eye, bleeding under your skin, or into your</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin (haematoma).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in your urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ulcers of your mouth or tongue.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes to your skin at the injection site. These include swelling, a hard lump, bruising,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into your skin (haematoma), rash, itching and changes in the skin colour.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness of your skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin infection (cellulitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An infection of the nose and throat, or sore throat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore or runny nose or sinuses (sinusitis)..</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High or low blood pressure (hypertension or hypotension).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being short of breath when you move.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in your throat and voicebox.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Indigestion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lethargy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling generally unwell.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being confused.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney failure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dehydration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; White coating covering tongue, inner cheeks, and sometimes on the roof of your mouth, gums</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and tonsils (oral fungal infection).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A fall in blood pressure when standing (orthostatic hypotension) leading to dizziness when</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moving to a standing or sitting position.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness, drowsiness (somnolence).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding due to a catheter line.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A disease affecting the gut which can result in fever, vomiting and stomach pain (diverticulitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid around the lungs (pleural effusion).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shivering (chills).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle spasms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised itchy rash on the skin (urticaria).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Collection of fluid around the heart (pericardial effusion)..</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic (hypersensitivity) reaction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shaking.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver failure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Large plum-coloured, raised painful patches on the skin with fever.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful skin ulceration (pyoderma gangrenosum).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the lining around the heart (pericarditis).</p><p>&nbsp;</p><p><strong>side effects </strong>(may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry cough.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painless swelling in the finger tips (clubbing).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tumour lysis syndrome - Metabolic complications that can occur during treatment of cancer and</p><p>sometimes even without treatment. These complications are caused by the product of dying</p><p>cancer cells and may include the following: changes to blood chemistry; high potassium,</p><p>phosphorus, uric acid, and low calcium consequently leading to changes in kidney function,</p><p>heartbeat, seizures, and sometimes death.</p><p>&nbsp;</p><p><strong>Not known (</strong>frequency cannot be estimated from the available data)</p><p>Infection of the deeper layers of skin, which spreads quickly, damaging the skin and tissue, which can</p><p>be life-threatening (necrotizing fasciitis).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the vial label and the carton. The</p><p>expiry date refers to the last day of that month.</p><p>Your doctor, pharmacist or nurse are responsible for storing Averaz. They are also responsible for</p><p>preparing and disposing of any unused Averaz correctly.</p><p>For unopened vials of this medicine &ndash; there are no special storage conditions.</p><p><em>When using immediately</em></p><p>Once the suspension has been prepared it should be administered within 45 minutes.</p><p><em>When using later on</em></p><p>If the Averaz suspension is prepared using water for injections that has not been refrigerated, the</p><p>suspension must be placed in the refrigerator (2 &deg;C &ndash; 8 &deg;C) immediately after it is prepared and kept</p><p>refrigerated for up to a maximum of 8 hours.</p><p>If the Averaz suspension is prepared using water for injections that has been stored in the refrigerator</p><p>(2 &deg;C &ndash; 8 &deg;C), the suspension must be placed in the refrigerator (2 &deg;C &ndash; 8 &deg;C) immediately after it is</p><p>prepared and kept refrigerated for up to a maximum of 22 hours.</p><p>&nbsp;</p><p>The suspension should be allowed up to 30 minutes prior to administration to reach room temperature</p><p>(20 &deg;C &ndash; 25 &deg;C).</p><p>If large particles are present in the suspension it should be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>a.What Averaz contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is azacitidine. One vial contains 100 mg azacitidine. After reconstitution</p><p>with 4 mL of water for injections, the reconstituted suspension contains 25 mg/mL azacitidine<em>.</em></p><p>The other ingredients are mannitol, Acetonitrile, water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                b.	b.What Averaz looks like and contents of the pack
Azacitidine for injection 100 mg/ vial is a white Lyophilized cake or powder and is supplied in 30 mL type-I with 20 mm moulded flint glass vial with 20 mm igloo design grey rubber stopper and sealed with aluminum seal having polypropylene disc. Such filled and labelled vial packed in unit carton along with package insert.
Pack size: Pack of 1 vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p><strong>&nbsp;</strong></p><p><strong>Manufactured by:</strong></p><p>MSN Laboratories Private Limited - India&nbsp; for MS Pharma - Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sep,2020
SPM190539

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما هو افيراز</p><p dir="RTL">يُعد دواء <strong>افيراز</strong> مضادًا للسرطان، وينتمي إلى مجموعة من الأدوية تُسمى مضادات الأيض. يحتوي افيراز على المادة الفعالة أزاسيتيدين.</p><p>&nbsp;</p><p>فيما يستخدم دواء افيراز</p><p dir="RTL">يستخدم دواء افيراز في المرضى غير القادرين على إجراء عملية زراعة الخلايا الجذعية لعلاج:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة خلل التنسج النخاعي / النقوي عالية الخطورة (MDS).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ابيضاض الدم / سرطان الدم الوحيدي النقوي المزمن (CMML).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ابيضاض الدم / سرطان الدم النقوي الحاد (AML).</p><p>&nbsp;</p><p dir="RTL">تؤثر هذه الأمراض على النخاع العظمي ويمكنها أن تسبب مشاكل في الإنتاج الطبيعي لخلايا الدم.</p><p>&nbsp;</p><p>كيف يعمل دواء افيراز</p><p dir="RTL">يعمل دواء افيراز من خلال منع الخلايا السرطانية من النمو.&nbsp; تتدخل مادة الأزاسيتيدين في المادة الوراثية للخلايا (الحمض النووي الريبوزي (RNA) والحمض النووي منقوص الأكسجين (DNA)) يُعتقد أنه يعمل عن طريق تغيير الطريقة التي تعمل بها الخلية على تنشيط الجينات وإيقافها وأيضًا عن طريق التدخل في الإنتاج الجديد للحمض النووي الريبوزي (RNA) والحمض النووي منقوص الأكسجين (DNA) . يُعتقد أن هذه التفاعلات تعدل من مشاكل نضوج ونمو خلايا الدم حديثة العمر في نخاع العظام الذي يتسبب في اضطرابات خلل التنسج النخاعي / النقوي، ويقتل الخلايا السرطانية في سرطان / ابيضاض الدم.</p><p dir="RTL">يرجى استشارة الطبيب أو الممرضة إذا كانت لديك أي أسئلة حول طريقة عمل هذا الدواء أو لماذا وصف لك خصيصًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما هي المعلومات التي يجب معرفتها قبل تناول دواء افيراز<br />لا تتناول دواء افيراز في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية مفرطة لمادة أزاسيتيدين أو لأي مكونات أخرى في هذا الدواء (من المكونات المذكورة في الفقرة 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من سرطان متقدم في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت سيدة تقوم بالرضاعة الطبيعية.</p><p>&nbsp;</p><p>التحذيرات والاحتياطات</p><p dir="RTL">استشر الطبيب أو الصيدلي أو الممرضة قبل تناول هذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نقص في عدد الصفائح الدموية أو كرات الدم الحمراء أو كرات الدم البيضاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض في الكلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق وعانيت من لمشكلة قلبية أو سكتة قلبية أو لديك أي تاريخ مرضي للإصابة بمرض رئوي.</p><p>&nbsp;</p><p dir="RTL"><u>فحوصات الدم</u></p><p dir="RTL">ستخضع لإجراء فحوصات الدم قبل بداية العلاج بهذا الدواء وعند بداية كل دورة من تناول الدواء.&nbsp; وذلك من أجل التحقق من أن لديك خلايا دم كافية وأن الكبد والكليتين يعملان بشكل صحيح.</p><p>&nbsp;</p><p>الأطفال والمراهقون</p><p dir="RTL">لا ينصح بتناول هذا الدواء في الأطفال والمراهقين الأصغر من 18 عاما.</p><p>&nbsp;</p><p>تناول أدوية أخرى مع دواء افيراز</p><p dir="RTL">يجب إخبار الطبيب أو الصيدليّ إذا كنت تتناول أدوية أو تناولت مؤخرًا بعض الأدوية أو تنوي تناول أي دواء آخر. وذلك لأن دواء افيراز يمكن أن يؤثر على طريقة عمل بعض الأدوية الأخرى. كما يمكن أيضا أن تؤثر بعض الأدوية على طريقة عمل دواء افيراز.</p><p>&nbsp;</p><p>الحمل والرضاعة الطبيعية والخصوبة</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">يجب تجنب تناول هذا الدواء أثناء الحمل، نظرًا لأنه قد يعرض الجنين للأذى.</p><p dir="RTL">لذا، يُنصح بضرورة استخدام وسيلة فعالة لمنع الحمل أثناء فترة تناول الدواء ولمدة 3 أشهر بعد الانتهاء من العلاج به. يجب إخبار الطبيب على الفور إذا أصبحت حاملا أثناء فترة العلاج بهذا الدواء.</p><p dir="RTL">يجب استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء في حالة السيدات الحوامل أو السيدات اللاتي تقمن بالرضاعة الطبيعية أو في حالات الاعتقاد بالحمل أو التخطيط لحدوث الحمل.</p><p>&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">يجب تجنب تناول هذا الدواء أثناء الرضاعة الطبيعية. لا نعلم إذا كان هذا الدواء يُفرز في لبن الأم أم لا.</p><p>&nbsp;</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">يجب على الرجال تجنب عملية الإنجاب أثناء العلاج بهذا الدواء. لذا، يُنصح بضرورة استخدام وسيلة فعالة لمنع الحمل أثناء فترة تناول الدواء ولمدة 3 أشهر بعد الانتهاء من العلاج به هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">يُنصح بالتحدث مع الطبيب إذا كنت ترغب في حفظ الحيوانات المنوية قبل بداية العلاج بهذا الدواء.</p><p>&nbsp;</p><p>القيادة واستخدام الآلات</p><p dir="RTL">يجب تجنب القيادة أو استخدام الآلات إذا عانيت من أي أعراض جانبية مثل التعب.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قبل البدء في تناول دواء افيراز، سيعطيك الطبيب دواء آخر لمنع الغثيان والقيء عند بداية كل دورة من العلاج.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي 75 ملغم لكل متر مربع من مساحة سطح الجسم. سيحدد الطبيب جرعة الدواء المناسبة بناء على حالتك العامة والطول والوزن. سيتابع الطبيب تقدم وتحسن حالتك وقد يحتاج إلى إجراء تعديل على جرعتك من الدواء إذا تطلب الأمر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تناول دواء افيراز كل يوم لمدة أسبوع، ويتبعها فترة راحة لمدة 3 أسابيع. سيتم تكرار هذه &quot;الدورة العلاجية&quot; كل 4 أسابيع. عادة ما ستخضع لست دورات علاجية على الأقل.</p><p>&nbsp;</p><p dir="RTL">ستتلقى هذا الدواء عبر الحقن تحت الجلد وبواسطة الطبيب أو الممرضة. قد يتم إعطاؤك هذا الدواء تحت الجلد في الفخذ أو البطن أو الجزء العلوي للذراع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى استشارة الطبيب أو الصيدلي أو الممرضة إذا كانت لديك أية أسئلة إضافية فيما يتعلق بتناول هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية، فإن هذا الدواء يمكن أن يتسبب في ظهور بعض الأعراض جانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضى.</p><p>&nbsp;</p><p>يجب إخبار الطبيب على الفور عند ملاحظة أي من هذه الأعراض الجانبية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار، الارتجاف، اليرقان (اصفرار الجلد)، انتفاخ البطن، سهولة تكون الكدمات. قد تكون هذه الأعراض تشير للإصابة بفشل كبدي، ويمكن أن تكون مهددة للحياة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الساقين والقدمين، آلام في الظهر، قلة مرور الماء عند التبول، زيادة العطش، سرعة النبض، دوار وغثيان، قيء أو قلة الشهية، الشعور بالارتباك، الأرق، التعب.<br />&nbsp;قد تكون هذه الأعراض تشير للإصابة بفشل كبدي، ويمكن أن تكون مهددة للحياة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة. قد يكون هذا بسبب التعرض للعدوى نتيجة لانخفاض مستويات خلايا الدم البيضاء، والذي يمكن أن يكون مهددًا للحياة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ألم في الصدر أو ضيق / قصر في التنفس قد يصاحبه ارتفاع في درجة الحرارة. قد يكون هذا بسبب عدوى في الرئة تسمى &quot;الالتهاب الرئوي&quot;، ويمكن أن تعرض حياتك للخطر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف. مثل وجود دم في البراز نتيجة نزيف في المعدة أو الأمعاء، أو نزيف داخل الرأس. قد تكون هذه الأعراض مؤشر لانخفاض مستويات الصفائح الدموية في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس، تورم الشفتين، حكة أو طفح جلدي. قد يكون هذا بسبب رد فعل تحسسي (فرط الحساسية).</p><p>&nbsp;</p><p dir="RTL">أعراض جانبية أخرى:</p><p dir="RTL"><strong>الأعراض الجانبية المألوفة جدا (قد تؤثر في أكثر من 1 من بين 10 أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد كرات الدم الحمراء (فقر الدم / أنيميا). قد تشعر بالإرهاق والشحوب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد كرات الدم البيضاء. قد يُصاحب ذلك الإصابة بارتفاع في درجة الحرارة. كما ستكون أيضًا أكثر عرضة للإصابة بالعدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في عدد الصفائح الدموية. ستكون أكثر عرضة للنزيف وتكون الكدمات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك، الإسهال، الغثيان، القيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر، قصر النفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب (الإرهاق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي في موضع الحقن، بما في ذلك الإصابة باحمرار أو ألم أو رد فعل جلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سهولة تكون الكدمات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع حمراء أو أرجوانية تحت الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم / التهاب في الأنف أو الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في النوم (أرق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الأنف (رُعاف).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف (الشعور بالوهن).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص مستويات البوتاسيوم في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية المألوفة (تؤثر في 1 من بين 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف من الرأس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في الدم تسببها البكتيريا (تسمم / تجرثم الدم). قد يكون ذلك بسبب نقص مستويات كرات الدم البيضاء في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل النخاع العظمي. يمكن أن يتسبب ذلك في نقص مستويات خلايا الدم الحمراء والبيضاء والصفائح الدموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد أنواع فقر الدم (الأنيميا) يحدث فيه نقص في عدد خلايا الدم الحمراء والبيضاء والصفائح الدموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في البول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فيروسية تتسبب في الإصابة بتقرحات البرد (عدوى فيروس الهربس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف اللثة، نزيف في المعدة أو الأمعاء، نزيف من أسفل الظهر بسبب البواسير (نزيف البواسير)، نزيف من العين، نزيف تحت الجلد، أو في الجلد (ورم دموي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم في البول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح في الفم أو اللسان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الجلد عند موضع الحقن. ويشمل ذلك التورم والكتل الصلبة والكدمات والنزيف في الجلد (ورم دموي) والطفح الجلدي والحكة وتغيرات في لون الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في الجلد (الالتهاب الخلوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في الأنف والحلق أو ألم / التهاب الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم / التهاب في الأنف أو سيلان الأنف (التهاب الجيوب الأنفية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع أو انخفاض ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بقصر النفس عند الحركة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الحلق والحنجرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر هضم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالخمول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور العام بالتوعّك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق أو اضطراب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بتشوش الذهن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقوط الشعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كلوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غطاء أبيض يغطي اللسان والخدود من الداخل وأحيانًا على سقف الفم واللثة واللوزتين (عدوى فطرية في الفم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في ضغط الدم عند الوقوف (نقص ضغط دم الانتصابي / القيامي) مما يؤدي إلى الشعور بالدوار عند الانتقال إلى وضعية الوقوف أو الجلوس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس، الشعور الدائم بالنعاس والدوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف عند تركيب قسطرة وريدية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض يصيب الأمعاء وقد ينتج عنه إصابة بارتفاع في درجة الحرارة وقيء وألم في المعدة (التهاب الرتج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع للسوائل حول الرئة (انصباب في الغشاء البلوري).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتجاف (الارتعاش).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات في العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مرتفع في الجلد يصاحبه شعور بالحكة (أرتيكاريا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع للسوائل حول القلب (انصباب قلبي).</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية غير المألوفة (تؤثر في 1 من بين 100 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي (فرط الحساسية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتجاف / الارتعاش.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كبدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع كبيرة مؤلمة بارزة بلون أرجواني (يشبه البرقوق) على الجلد مصحوبة بالحمى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرح مؤلم في الجلد (تقيح الجلد الغنغريني).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في الغشاء المحيط بالقلب (التهاب التامور).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية النادرة (تؤثر في 1 من بين 1000 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال جاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم غير مؤلم في أطراف الأصابع (تعجر).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة انحلال الورم - المضاعفات الأيضية التي يمكن أن تحدث أثناء علاج السرطان وأحيانًا حتى بدون العلاج. تحدث هذه المضاعفات نتيجة موت الخلايا السرطانية وقد تشمل ما يلي: تغييرات في كيمياء الدم؛ ارتفاع مستوى البوتاسيوم والفوسفور وحمض البوليك وانخفاض مستوى الكالسيوم مما يؤدي إلى تغيرات في وظائف الكلى ونبض القلب والنوبات الصرعية وأحيانًا قد يؤدي إلى الموت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية غير المعروفة (لا يمكن تحديد نسبة تكرار الأعراض من البيانات المتاحة)</strong></p><p dir="RTL">إصابة الطبقات العميقة من الجلد، والتي تنتشر بسرعة، مما يؤدي إلى تلف الجلد والأنسجة، مما قد يعرض الحياة للخطر (التهاب اللفافة الناخر).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضح على شريطة&nbsp; العبوة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير في الشهر.</p><p dir="RTL">الطبيب أو الصيدلي أو الممرض هم المسئولون عن حفظ وتخزين الدواء. بالإضافة إلى أنهم المسؤولين عن التخلص السليم من الجرعات المتبقية غير المستخدمة من هذا الدواء.</p><p dir="RTL">بالنسبة للعبوة غير المفتوحة لهذا الدواء - لا توجد شروط حفظ وتخزين خاصة.</p><p dir="RTL">عند استخدام الدواء في الحال</p><p dir="RTL">يجب استخدام الدواء في غضون 45 دقيقة بمجرد إعداد المحلول.</p><p dir="RTL">عند استخدام الدواء فيما بعد</p><p dir="RTL">إذا تم إعداد محلول الدواء باستخدام ماء من أجل الحقن لم يتم تبريده، يجب وضع المحلول في الثلاجة (عند درجة حرارة 2 إلى 8 درجة مئوية) على الفور بعد تجهيزه، ويجب أن يتم حفظه في الثلاجة لمدة لا تزيد عن 8 ساعات.</p><p dir="RTL">إذا تم إعداد محلول الدواء باستخدام ماء من أجل الحقن وقد تم تبريده في الثلاجة (عند درجة حرارة 2 إلى 8 درجة مئوية)، يجب وضع المحلول في الثلاجة (عند درجة حرارة 2 إلى 8 درجة مئوية) على الفور بعد تجهيزه، ويجب أن يتم حفظه في الثلاجة لمدة لا تزيد عن 22 ساعة.</p><p dir="RTL">يجب ترك المحلول لمدة تصل إلى 30 دقيقة قبل الاستخدام، حتى يصل إلى درجة حرارة الغرفة (20 إلى 25 درجة مئوية).</p><p>يجب التخلص من المحلول إذا لوحظ فيه بعض الجسيمات الكبيرة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>محتويات العبوّة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة: أزاسيتيدين. تحتوي العبوة الواحدة على 100 ملغم من مادة أزاسيتيدين. بعد إذابة الدواء مع 4 مل من الماء المُعد للحقن، سيحتوي المحلول المذاب على 25 ملغم / مل من مادة أزاسيتيدين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باقي المكونات مانيتول وأسيتونتريل والماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحتوي عبوة ازاسيتيدين الواحد على 100 ملغم وهو مسحوق أبيض مجفف بالتبريد ويتم توفيره في 30 مل من النوع الأول مع قارورة زجاجية ذات مصبوب وسدادة تحتوي على 20 مل مع زجاجة اخرى مجمدة وذات سدادة مطاطية ويحتوي على 20ملم ومغلق بغطاء من الألمونيوم مع قرص البولي بروبلين. تعد هذه القارورة مملوءة ومعبأة في علبة كرتونية مع إدراج النشرة المرفقة بالعبوة.</p><p dir="RTL">حجم العبوة: عبوة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>الرياض ، المملكة العربية السعودية .</p><p dir="RTL">&nbsp;&nbsp;&nbsp; info-ksa@mspharma.com</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>صنعت بواسطة </strong><strong>: </strong></p><p dir="RTL">مختبرات إم إس إن&nbsp;&nbsp; الخاصة المحدودة &ndash; الهند&nbsp; لصالح إم إس فارما &ndash; المملكة العربية السعودية .</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر،2020
SPM190539


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Averaz ® for Injection 100 mg/vial.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains Azacitidine 100 mg. After reconstitution, each mL of suspension contains 25 mg
azacitidine.
For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lyophilized powder for Injection.
White Lyophilized cake or powder in 30 mL type I with 20 mm moulded flint glass vial with 20
mm igloo design grey rubber stopper and sealed with aluminium seal having polypropylene disc.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell</p><p>transplantation (HSCT) with:</p><p> intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International</p><p>Prognostic Scoring System (IPSS),</p><p> chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without</p><p>myeloproliferative disorder,</p><p> acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to</p><p>World Health Organisation (WHO) classification,</p><p> AML with &gt;30% marrow blasts according to the WHO classification.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vidaza treatment should be initiated and monitored under the supervision of a physician experienced</p><p>in the use of chemotherapeutic agents. Patients should be premedicated with anti-emetics for nausea</p><p>and vomiting.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Posology</u></p><p>The recommended starting dose for the first treatment cycle, for all patients regardless of baseline haematology laboratory values, is 75 mg/m2&nbsp;of body surface area, injected subcutaneously, daily for 7 days, followed by a rest period of 21 days (28-day treatment cycle).</p><p>It is recommended that patients be treated for a minimum of 6 cycles. Treatment should be continued</p><p>as long as the patient continues to benefit or until disease progression.</p><p>Patients should be monitored for haematologic response/toxicity and renal toxicities (see section 4.4);</p><p>a delay in starting the next cycle or a dose reduction as described below may be necessary.</p><p><u>Laboratory tests</u></p><p>Liver function tests, serum creatinine and serum bicarbonate should be determined prior to initiation</p><p>of therapy and prior to each treatment cycle. Complete blood counts should be performed prior to</p><p>initiation of therapy and as needed to monitor response and toxicity, but at a minimum, prior to each</p><p>treatment cycle.</p><p>&nbsp;</p><p><strong>Dosage Adjustment due to haematological toxicity</strong></p><p>Haematological toxicity is defined as the lowest count reached in a given cycle (nadir) if platelets</p><p>&le; 50.0 x 10<sup>9</sup>/l and/or absolute neutrophil count (ANC) &le; 1 x 10<sup>9</sup>/l.</p><p>&nbsp;</p><p>Recovery is defined as an increase of cell line(s) where haematological toxicity was observed of at</p><p>least half of the difference of nadir and the baseline count plus the nadir count (i.e. blood count at</p><p>recovery &ge; nadir count + (0.5 x [baseline count &ndash; nadir count]).</p><p>&nbsp;</p><p>Patients without reduced baseline blood counts (i.e. White Blood Cells (WBC) &ge; 3.0 x 109/l and</p><p>ANC &ge; 1.5 x 10<sup>9</sup>/l, and platelets &ge; 75.0 x 10<sup>9</sup>/l) prior to the first treatment</p><p>If haematological toxicity is observed following Vidaza treatment, the next cycle of the therapy should</p><p>be delayed until the platelet count and the ANC have recovered. If recovery is achieved within</p><p>14 days, no dose adjustment is necessary. However, if recovery has not been achieved within 14 days,</p><p>the dose should be reduced according to the following table. Following dose modifications, the cycle</p><p>duration should return to 28 days.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Nadir Counts</p></td><td rowspan="2" style="vertical-align:top"><p>% Dose in the next cycle, if not achieved within 14 days</p></td></tr><tr><td style="vertical-align:top"><p>ANC( x 109/L)</p></td><td style="vertical-align:top"><p>Platelets (x 109/L)</p></td></tr><tr><td style="vertical-align:top"><p>&le; 1.0</p></td><td style="vertical-align:top"><p>&le; 50.0</p></td><td style="vertical-align:top"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 1.0</p></td><td style="vertical-align:top"><p>&gt; 50.0</p></td><td style="vertical-align:top"><p>100%</p></td></tr></tbody></table><p>*Recovery = counts &ge; nadir count + (0.5 x [baseline count &ndash; nadir count])</p><p>Patients with reduced baseline blood counts (i.e. WBC &lt; 3.0 x 10<sup>9</sup>/l or ANC &lt; 1.5 x 10<sup>9</sup>/l or platelets</p><p>&lt; 75.0 x 10<sup>9</sup>/l) prior to the first treatment</p><p>Following Vidaza treatment, if the decrease in WBC or ANC or platelets from that prior to treatment</p><p>is &le; 50 %, or greater than 50 % but with an improvement in any cell line differentiation, the next cycle</p><p>should not be delayed and no dose adjustment made.</p><p>&nbsp;</p><p>If the decrease in WBC or ANC or platelets is greater than 50 % from that prior to treatment, with no</p><p>improvement in cell line differentiation, the next cycle of Vidaza therapy should be delayed until the</p><p>platelet count and the ANC have recovered. If recovery is achieved within 14 days, no dose</p><p>adjustment is necessary. However, if recovery has not been achieved within 14 days, bone marrow</p><p>cellularity should be determined. If the bone marrow cellularity is &gt; 50 %, no dose adjustments should</p><p>be made. If bone marrow cellularity is &le; 50 %, treatment should be delayed and the dose reduced</p><p>according to the following table:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Bone marrow cellularity</p></td><td colspan="2" style="vertical-align:top"><p>% Dose in the next cycle if recovery is not achieved within 14 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Recovery* &le; 21 days</p></td><td style="vertical-align:top"><p>Recovery* &gt; 21 days</p></td></tr><tr><td style="vertical-align:top"><p>15-50 %</p></td><td style="vertical-align:top"><p>100 %</p></td><td style="vertical-align:top"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 15 %</p></td><td style="vertical-align:top"><p>100 %</p></td><td style="vertical-align:top"><p>33%</p></td></tr></tbody></table><p>&nbsp;</p><p>*Recovery = counts &ge; nadir count + (0.5 x [baseline count &ndash; nadir count])</p><p>Following dose modifications, the cycle duration should return to 28 days.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>Elderly patients</p><p>No specific dose adjustments are recommended for the elderly. Because elderly patients are more</p><p>likely to have decreased renal function, it may be useful to monitor renal function.</p><p>&nbsp;</p><p><u>Patients with renal impairment</u></p><p>Azacitidine can be administered to patients with renal impairment without initial dose adjustment (see</p><p>section 5.2). If unexplained reductions in serum bicarbonate levels to less than 20 mmol/l occur, the</p><p>dose should be reduced by 50 % on the next cycle. If unexplained elevations in serum creatinine or</p><p>blood urea nitrogen (BUN) to &ge; 2-fold above baseline values and above upper limit of normal (ULN)</p><p>occur, the next cycle should be delayed until values return to normal or baseline and the dose should</p><p>be reduced by 50 % on the next treatment cycle (see section 4.4).</p><p><u>Patients with hepatic impairment</u></p><p>No formal studies have been conducted in patients with hepatic impairment (see section 4.4). Patients</p><p>with severe hepatic organ impairment should be carefully monitored for adverse events. No specific</p><p>modification to the starting dose is recommended for patients with hepatic impairment prior to starting</p><p>treatment; subsequent dose modifications should be based on haematology laboratory values. Vidaza</p><p>is contraindicated in patients with advanced malignant hepatic tumours (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety and efficacy of Vidaza in children aged 0-17 years have not yet been established. No data</p><p>are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Reconstituted Vidaza should be injected subcutaneously into the upper arm, thigh or abdomen.</p><p>Injection sites should be rotated. New injections should be given at least 2.5 cm from the previous site</p><p>and never into areas where the site is tender, bruised, red, or hardened.</p><p>After reconstitution, the suspension should not be filtered. For instructions on reconstitution of the</p><p>medicinal product before administration, see section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Advanced malignant hepatic tumours (see section 4.4).
Breast-feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Haematological toxicity</u></p><p>Treatment with azacitidine is associated with anaemia, neutropenia and thrombocytopenia, particularly</p><p>during the first 2 cycles (see section 4.8). Complete blood counts should be performed as needed to</p><p>monitor response and toxicity, but at least prior to each treatment cycle. After administration of the</p><p>recommended dose for the first cycle, the dose for subsequent cycles should be reduced or its</p><p>administration delayed based on nadir counts and haematological response (see section 4.2). Patients</p><p>should be advised to promptly report febrile episodes. Patients and physicians are also advised to be</p><p>observant for signs and symptoms of bleeding.</p><p><u>Hepatic impairment</u></p><p>No formal studies have been conducted in patients with hepatic impairment. Patients with extensive</p><p>tumour burden due to metastatic disease have been reported to experience progressive hepatic coma</p><p>and death during azacitidine treatment, especially in such patients with baseline serum albumin</p><p>&lt; 30 g/L. Azacitidine is contraindicated in patients with advanced malignant hepatic tumours (see</p><p>section 4.3).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Renal abnormalities ranging from elevated serum creatinine to renal failure and death were reported in</p><p>patients treated with intravenous azacitidine in combination with other chemotherapeutic agents. In</p><p>addition, renal tubular acidosis, defined as a fall in serum bicarbonate to &lt; 20 mmol/L in association</p><p>with an alkaline urine and hypokalaemia (serum potassium &lt; 3 mmol/L) developed in 5 subjects with</p><p>chronic myelogenous leukaemia (CML) treated with azacitidine and etoposide. If unexplained</p><p>reductions in serum bicarbonate (&lt; 20 mmol/L) or elevations of serum creatinine or BUN occur, the</p><p>dose should be reduced or administration delayed (see section 4.2).</p><p>Patients should be advised to report oliguria and anuria to the health care provider immediately.</p><p>&nbsp;</p><p>Although no clinically relevant differences in the frequency of adverse reactions were noted between</p><p>subjects with normal renal function compared to those with renal impairment, patients with renal</p><p>impairment should be closely monitored for toxicity since azacitidine and/or its metabolites are</p><p>primarily excreted by the kidney (see section 4.2).</p><p>&nbsp;</p><p><u>Laboratory tests</u></p><p>Liver function tests, serum creatinine and serum bicarbonate should be determined prior to initiation</p><p>of therapy and prior to each treatment cycle. Complete blood counts should be performed prior to</p><p>initiation of therapy and as needed to monitor response and toxicity, but at a minimum, prior to each</p><p>treatment cycle, see also section 4.8.</p><p>&nbsp;</p><p><u>Cardiac and pulmonary disease</u></p><p>Patients with a history of severe congestive heart failure, clinically unstable cardiac disease or</p><p>pulmonary disease were excluded from the pivotal registration studies (AZA PH GL 2003 CL 001 and</p><p>AZA-AML-001) and therefore the safety and efficacy of azacitidine in these patients has not been</p><p>established. Recent data from a clinical trial in patients with a known history of cardiovascular or</p><p>pulmonary disease showed a significantly increased incidence of cardiac events with azacitidine (see</p><p>section 4.8). It is therefore advised to exercise caution when prescribing azacitidine to these patients.</p><p>Cardiopulmonary assessment before and during the treatment should be considered.</p><p>&nbsp;</p><p><u>Necrotising fasciitis</u></p><p>Necrotising fasciitis, including fatal cases, have been reported in patients treated with Vidaza. Vidaza</p><p>therapy should be discontinued in patients who develop necrotising fasciitis and appropriate treatment</p><p>should be promptly initiated.</p><p>&nbsp;</p><p><u>Tumour lysis syndrome</u></p><p>The patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment.</p><p>These patients should be monitored closely and appropriate precautions taken.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on in vitro data, azacitidine metabolism does not appear to be mediated by cytochrome P450</p><p>isoenzymes (CYPs), UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), and</p><p>glutathione transferases (GSTs); interactions related to these metabolizing enzymes in vivo are</p><p>therefore considered unlikely.</p><p>Clinically significant inhibitory or inductive effects of azacitidine on cytochrome P450 enzymes are</p><p>unlikely (see section 5.2).</p><p>No formal clinical drug interaction studies with azacitidine have been conducted</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / Contraception in males and females</u></p><p>Women of childbearing potential and men have to use effective contraception during and up to</p><p>3 months after treatment.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are no adequate data from the use of azacitidine in pregnant women. Studies in mice have</p><p>shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Based on</p><p>results from animal studies and its mechanism of action, azacitidine should not be used during</p><p>pregnancy, especially during the first trimester, unless clearly necessary. The advantages of treatment</p><p>should be weighed against the possible risk for the foetus in every individual case.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether azacitidine/metabolites are excreted in human milk. Due to the potential serious</p><p>adverse reactions in the nursing child, breast-feeding is contraindicated during azacitidine therapy.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no human data on the effect of azacitidine on fertility. In animals, adverse reactions with</p><p>azacitidine use on male fertility have been documented (see section 5.3). Men should be advised not to</p><p>father a child while receiving treatment and must use effective contraception during and up to</p><p>3 months after treatment. Before starting treatment, male patients should be advised to seek</p><p>counselling on sperm storage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azacitidine has minor or moderate influence on the ability to drive and use machines. Fatigue has been reported with the use of azacitidine. Therefore, caution is recommended when driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Adult population with MDS, CMML and AML (20-30% marrow blasts)</p><p>Adverse reactions considered to be possibly or probably related to the administration of Vidaza have</p><p>occurred in 97 % of patients.</p><p>&nbsp;</p><p>The most common serious adverse reactions noted from the pivotal study (AZA PH GL 2003 CL 001)</p><p>included febrile neutropenia (8.0 %) and anaemia (2.3 %), which were also reported in the supporting</p><p>studies (CALGB 9221 and CALGB 8921). Other serious adverse reactions from these 3 studies</p><p>included infections such as neutropenic sepsis (0.8%) and pneumonia (2.5%) (some with fatal</p><p>outcome), thrombocytopenia (3.5%), hypersensitivity reactions (0.25%) and haemorrhagic events (e.g.</p><p>cerebral haemorrhage [0.5%], gastrointestinal haemorrhage [0.8%] and intracranial haemorrhage</p><p>[0.5%])).</p><p>The most commonly reported adverse reactions with azacitidine treatment were haematological</p><p>reactions (71.4 %) including thrombocytopenia, neutropenia and leukopenia (usually Grade 3-4),</p><p>gastrointestinal events (60.6 %) including nausea, vomiting (usually Grade 1-2) or injection site</p><p>reactions (77.1 %; usually Grade 1-2).</p><p>&nbsp;</p><p>Adult population aged 65 years or older with AML with &gt; 30% marrow blasts</p><p>The most common serious adverse reactions (&ge; 10%) noted from AZA-AML-001 within the</p><p>azacitidine treatment arm included febrile neutropenia (25.0%), pneumonia (20.3%), and pyrexia</p><p>(10.6%). Other less frequently reported serious adverse reactions in the azacitidine treatment arm</p><p>included sepsis (5.1%), anaemia (4.2%), neutropenic sepsis (3.0%), urinary tract infection (3.0%),</p><p>thrombocytopenia (2.5%), neutropenia (2.1%), cellulitis (2.1%), dizziness (2.1%) and</p><p>dyspnoea (2.1%).</p><p>&nbsp;</p><p>The most commonly reported (&ge; 30%) adverse reactions with azacitidine treatment were</p><p>gastrointestinal events, including constipation (41.9%), nausea (39.8%), and diarrhoea (36.9%),</p><p>(usually Grade 1-2), general disorders and administration site conditions including pyrexia (37.7%;</p><p>usually Grade 1-2) and haematological events, including febrile neutropenia (32.2%) and neutropenia</p><p>(30.1%), (usually Grade 3-4).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Table 1 below contains adverse reactions associated with azacitidine treatment obtained from the main</p><p>clinical studies in MDS and AML and post marketing surveillance.</p><p>&nbsp;</p><p>Frequencies are defined as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10); uncommon</p><p>(&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be</p><p>estimated from the available data). Within each frequency grouping, undesirable effects are presented</p><p>in order of decreasing seriousness. Adverse reactions are presented in the table below according to the</p><p>highest frequency observed in any of the main clinical studies.</p><p>&nbsp;</p><p><strong>Table 1: ADRs reported in patients with MDS or AML treated with azacitidine (clinical</strong></p><p><strong>studies and post- marketing)</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; * = rarely fatal cases have been reported</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>Haematologic adverse reactions</p><p>The most commonly reported (&ge; 10%) haematological adverse reactions associated with azacitidine</p><p>treatment include anaemia, thrombocytopenia, neutropenia, febrile neutropenia and leukopenia, and</p><p>were usually Grade 3 or 4. There is a greater risk of these events occurring during the first 2 cycles,</p><p>after which they occur with less frequency in patients with restoration of haematological function.</p><p>Most haematological adverse reactions were managed by routine monitoring of complete blood counts</p><p>and delaying azacitidine administration in the next cycle, prophylactic antibiotics and/or growth factor</p><p>support (e.g. G-CSF) for neutropenia and transfusions for anaemia or thrombocytopenia as required.</p><p>&nbsp;</p><p><u>Infections</u></p><p>Myelosuppression may lead to neutropenia and an increased risk of infection. Serious adverse</p><p>reactions such as sepsis, including neutropenic sepsis, and pneumonia were reported in patients</p><p>receiving azacitidine, some with a fatal outcome. Infections may be managed with the use of antiinfectives plus growth factor support (e.g. G-CSF) for neutropenia.</p><p>&nbsp;</p><p><u>Bleeding</u></p><p>Bleeding may occur with patients receiving azacitidine. Serious adverse reactions such as</p><p>gastrointestinal haemorrhage and intracranial haemorrhage have been reported. Patients should be</p><p>monitored for signs and symptoms of bleeding, particularly those with pre-existing or treatmentrelated</p><p>thrombocytopenia.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Serious hypersensitivity reactions have been reported in patients receiving azacitidine. In case of an</p><p>anaphylactic-like reaction, treatment with azacitidine should be immediately discontinued and</p><p>appropriate symptomatic treatment initiated.</p><p>&nbsp;</p><p><u>Skin and subcutaneous tissue adverse reactions</u></p><p>The majority of skin and subcutaneous adverse reactions were associated with the injection site. None</p><p>of these adverse reactions led to discontinuation of azacitidine, or reduction of azacitidine dose in the</p><p>pivotal studies. The majority of adverse reactions occurred during the first 2 cycles and tended to</p><p>decrease with subsequent cycles. Subcutaneous adverse reactions such as injection site</p><p>rash/inflammation/pruritus, rash, erythema and skin lesion may require management with concomitant</p><p>medicinal products, such as antihistamines, corticosteroids and non-steroidal anti-inflammatory</p><p>medicinal products (NSAIDs). These cutaneous reactions have to be distinguished from soft tissue</p><p>infections, sometimes occurring at injection site. Soft tissue infections, including cellulitis and</p><p>necrotising fasciitis in rare cases leading to death, have been reported with azacitidine in the post</p><p>marketing setting. For clinical management of infectious adverse reactions, see section 4.8 Infections.</p><p>&nbsp;</p><p><u>Gastrointestinal adverse reactions</u></p><p>The most commonly reported gastrointestinal adverse reactions associated with azacitidine treatment</p><p>included constipation, diarrhoea, nausea and vomiting. These adverse reactions were managed</p><p>symptomatically with anti-emetics for nausea and vomiting; anti-diarrhoeals for diarrhoea, and</p><p>laxatives and/or stool softeners for constipation.</p><p>&nbsp;</p><p><u>Renal adverse reactions</u></p><p>Renal abnormalities, ranging from elevated serum creatinine and haematuria to renal tubular acidosis,</p><p>renal failure and death were reported in patients treated with azacitidine (see section 4.4).</p><p>&nbsp;</p><p><u>Hepatic adverse reactions</u></p><p>Patients with extensive tumour burden due to metastatic disease have been reported to experience</p><p>hepatic failure, progressive hepatic coma and death during azacitidine treatment (see section 4.4).</p><p>&nbsp;</p><p><u>Cardiac events</u></p><p>Data from a clinical trial allowing enrolment of patients with known history of cardiovascular or</p><p>pulmonary disease showed a statistically significant increase in cardiac events in patients with newly</p><p>diagnosed AML treated with azacitidine (see section 4.4).</p><p>&nbsp;</p><p><u>Elderly population</u></p><p>There is limited safety information available with azacitidine in patients &ge;85 years (with 14 [5.9%]</p><p>patients &ge;85 years in AZA-AML-001 study).</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s)</strong>:</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>- The National Pharmacovigilance and Drug Safety Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>One case of overdose with Azacitidine was reported during clinical trials. A patient experienced</p><p>diarrhea, nausea, and vomiting after receiving a single intravenous dose of approximately 290</p><p>mg/m2, almost 4 times the recommended starting dose. The event resolved without sequelae, and</p><p>the correct dose was resumed the following day.</p><p>In the event of overdose, the patient should be monitored with appropriate blood counts and should receive supportive treatment, as necessary. There is no known specific antidote for Azacitidine overdose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, pyrimidine analogues; ATC code: L01BC07</p><p><strong><u>Mechanism of action</u></strong></p><p dir="RTL">Azacitidine is a pyrimidine nucleoside analog of cytidine. Azacitidine is believed to exert its Azacitidine is believed to exert its antineoplastic effects by multiple mechanisms including</p><p dir="RTL">cytotoxicity on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA. The</p><p dir="RTL">cytotoxic effects of azacitidine may result from multiple mechanisms, including inhibition of DNA,</p><p dir="RTL">RNA and protein synthesis, incorporation into RNA and DNA, and activation of DNA damage</p><p dir="RTL">pathways. Non-proliferating cells are relatively insensitive to azacitidine. Incorporation of azacitidine</p><p dir="RTL">into DNA results in the inactivation of DNA methyltransferases, leading to hypomethylation of DNA.</p><p dir="RTL">DNA hypomethylation of aberrantly methylated genes involved in normal cell cycle regulation,</p><p dir="RTL">differentiation and death pathways may result in gene re-expression and restoration of cancersuppressing</p><p dir="RTL">functions to cancer cells. The relative importance of DNA hypomethylation versus</p><p dir="RTL">cytotoxicity or other activities of azacitidine to clinical outcomes has not been established 5.2<strong> </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>Clinical efficacy and safety</u></p><p dir="RTL">Adult population (MDS, CMML and AML [20-30% marrow blasts])</p><p dir="RTL">The efficacy and safety of Vidaza were studied in an international, multicenter, controlled, open-label,</p><p dir="RTL">randomised, parallel-group, Phase 3 comparative study (AZA PH GL 2003 CL 001) in adult patients</p><p dir="RTL">with: intermediate-2 and high-risk MDS according to the International Prognostic Scoring System</p><p dir="RTL">(IPSS), refractory anaemia with excess blasts (RAEB), refractory anaemia with excess blasts in</p><p dir="RTL">transformation (RAEB-T) and modified chronic myelomonocytic leukaemia (mCMML) according to</p><p dir="RTL">the French American British (FAB) classification system. RAEB-T patients (21-30 % blasts) are now</p><p dir="RTL">considered to be AML patients under the current WHO classification system. Azacitidine plus best</p><p dir="RTL">supportive care (BSC) (n = 179) was compared to conventional care regimens (CCR). CCR consisted</p><p dir="RTL">of BSC alone (n = 105), low-dose cytarabine plus BSC (n = 49) or standard induction chemotherapy</p><p dir="RTL">plus BSC (n = 25). Patients were pre-selected by their physician to 1 of the 3 CCR prior to</p><p dir="RTL">randomisation. Patients received this pre-selected regimen if not randomised to Vidaza. As part of the</p><p dir="RTL">inclusion criteria, patients were required to have an Eastern Cooperative Oncology Group (ECOG)</p><p dir="RTL">performance status of 0-2. Patients with secondary MDS were excluded from the study. The primary</p><p dir="RTL">endpoint of the study was overall survival. Vidaza was administered at a subcutaneous dose of</p><p dir="RTL">75 mg/m2 daily for 7 days, followed by a rest period of 21 days (28-day treatment cycle) for a median</p><p dir="RTL">of 9 cycles (range = 1-39) and a mean of 10.2 cycles. Within the Intent to Treat population (ITT), the</p><p dir="RTL">median age was 69 years (range 38 to 88 years).</p><p dir="RTL">In the ITT analysis of 358 patients (179 azacitidine and 179 CCR), Vidaza treatment was associated</p><p dir="RTL">with a median survival of 24.46 months versus 15.02 months for those receiving CCR treatment, a</p><p dir="RTL">difference of 9.4 months, with a stratified log-rank p-value of 0.0001. The hazard ratio for the</p><p dir="RTL">treatment effect was 0.58 (95 % CI: 0.43, 0.77). The two-year survival rates were 50.8 % in patients</p><p dir="RTL">receiving azacitidine versus 26.2 % in patients receiving CCR (p &lt; 0.0001).</p><p dir="RTL">&nbsp;</p><p>KEY: AZA = azacitidine; CCR = conventional care regimens; CI = confidence interval;</p><p>HR = hazard ratio</p><p>The survival benefits of Vidaza were consistent regardless of the CCR treatment option (BSC alone,</p><p>low-dose cytarabine plus BSC or standard induction chemotherapy plus BSC) utilised in the</p><p>control arm.</p><p>When IPSS cytogenetic subgroups were analysed, similar findings in terms of median overall survival</p><p>were observed in all groups (good, intermediate, poor cytogenetics, including monosomy 7).</p><p>On analyses of age subgroups, an increase in median overall survival was observed for all groups</p><p>(&lt; 65 years, &ge; 65 years and &ge; 75 years).</p><p>Vidaza treatment was associated with a median time to death or transformation to AML of</p><p>13.0 months versus 7.6 months for those receiving CCR treatment, an improvement of 5.4 months</p><p>with a stratified log-rank p-value of 0.0025.</p><p>Vidaza treatment was also associated with a reduction in cytopenias, and their related symptoms.</p><p>Vidaza treatment led to a reduced need for red blood cell (RBC) and platelet transfusions. Of the</p><p>patients in the azacitidine group who were RBC transfusion dependent at baseline, 45.0 % of these</p><p>patients became RBC transfusion independent during the treatment period, compared with 11.4 % of</p><p>the patients in the combined CCR groups (a statistically significant (p &lt; 0.0001) difference of 33.6 %</p><p>(95 % CI: 22.4, 44.6). In patients who were RBC transfusion dependent at baseline and became</p><p>independent, the median duration of RBC transfusion independence was 13 months in the</p><p>azacitidine group.</p><p>&nbsp;</p><p>Response was assessed by the investigator or by the Independent Review Committee (IRC). Overall</p><p>response (complete remission [CR] + partial remission [PR]) as determined by the investigator was</p><p>29 % in the azacitidine group and 12% in the combined CCR group (p = 0.0001). Overall response</p><p>(CR + PR) as determined by the IRC in AZA PH GL 2003 CL 001 was 7 % (12/179) in the azacitidine</p><p>group compared with 1 % (2/179) in the combined CCR group (p = 0.0113). The differences between</p><p>the IRC and investigator assessments of response were a consequence of the International Working</p><p>Group (IWG) criteria requiring improvement in peripheral blood counts and maintenance of these</p><p>improvements for a minimum of 56 days. A survival benefit was also demonstrated in patients that</p><p>had not achieved a complete/partial response following azacitidine treatment. Haematological</p><p>improvement (major or minor) as determined by the IRC was achieved in 49 % of patients receiving</p><p>azacitidine compared with 29 % of patients treated with combined CCR (p &lt; 0.0001).</p><p>In patients with one or more cytogenetic abnormalities at baseline, the percentage of patients with a</p><p>major cytogenetic response was similar in the azacitidine and combined CCR groups. Minor</p><p>cytogenetic response was statistically significantly (p = 0.0015) higher in the azacitidine group (34 %)</p><p>compared with the combined CCR group (10 %).</p><p>&nbsp;</p><p>Adult population aged 65 years or older with AML with &gt; 30% marrow blasts</p><p>The results presented below represent the intent-to-treat population studied in AZA-AML-001 (see</p><p>section 4.1 for the approved indication).</p><p>&nbsp;</p><p>The efficacy and safety of Vidaza was studied in an international, multicentre, controlled, open-label,</p><p>parallel group Phase 3 study in patients 65 years and older with newly diagnosed de novo or secondary</p><p>AML with &gt;30% bone marrow blasts according to the WHO classification, who were not eligible for</p><p>HSCT. Vidaza plus BSC (n=241) was compared to CCR. CCR consisted of BSC alone (n=45), lowdose</p><p>cytarabine plus BSC (n=158), or standard intensive chemotherapy with cytarabine and</p><p>anthracycline plus BSC (n=44). Patients were pre-selected by their physician to 1 of the 3 CCRs prior</p><p>to randomization. Patients received the pre-selected regimen if not randomised to Vidaza. As part of</p><p>the inclusion criteria, patients were required to have an ECOG performance status of 0-2 and</p><p>intermediate- or poor-risk cytogenetic abnormalities. The primary endpoint of the study was</p><p>overall survival.</p><p>&nbsp;</p><p>Vidaza was administered at a SC dose of 75mg/m2/day for 7 days, followed by a rest period of 21 days</p><p>(28 day treatment cycle), for a median of 6 cycles (range: 1 to 28), BSC- only patients for a median of</p><p>3 cycles (range: 1 to 20), low-dose cytarabine patients for a median of 4 cycles (range 1 to 25) and</p><p>standard intensive chemotherapy patients for a median of 2 cycles (range: 1 to 3, induction cycle plus</p><p>1 or 2 consolidation cycles).</p><p>&nbsp;</p><p>The individual baseline parameters were comparable between the Vidaza and CCR groups. The</p><p>median age of the subjects was 75.0 years (range: 64 to 91 years), 75.2% were Caucasian and 59.0%</p><p>were male. At baseline 60.7% were classified as AML not otherwise specified, 32.4% AML with</p><p>myelodysplasia-related changes, 4.1% therapy-related myeloid neoplasms and 2.9% AML with</p><p>recurrent genetic abnormalities according to the WHO classification.</p><p>&nbsp;</p><p>In the ITT analysis of 488 patients (241 Vidaza and 247 CCR), Vidaza treatment was associated with a</p><p>median survival of 10.4 months versus 6.5 months for those receiving CCR treatment, a difference of</p><p>3.8 months, with a stratified log-rank p-value of 0.1009 (two- sided). The hazard ratio for the</p><p>treatment effect was 0.85 (95% CI= 0.69, 1.03). The one-year survival rates were 46.5% in patients</p><p>receiving Vidaza versus 34.3% in patients receiving CCR.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p>The Cox PH model adjusted for pre-specified baseline prognostic factors defined a HR for Vidaza</p><p>versus CCR of 0.80 (95% CI= 0.66, 0.99; p = 0.0355).</p><p>&nbsp;</p><p>In addition, although the study was not powered to demonstrate a statistically significant difference</p><p>when comparing azacitidine to the preselection CCR treatment groups, the survival of Vidaza treated</p><p>patients was longer when compared to CCR treatment options BSC alone, low-dose cytarabine plus</p><p>BSC and were similar when compared to standard intensive chemotherapy plus BSC.</p><p>&nbsp;</p><p>In all pre- specified subgroups age [(&lt; 75 years &amp; &ge; 75 years), gender, race, ECOG performance status</p><p>(0 or 1 &amp; 2) , baseline cytogenetic risk (intermediate &amp; poor) , geographic region, WHO classification</p><p>of AML (including AML with myelodysplasia-related changes), baseline WBC count (&le; 5 x109/L &amp;</p><p>&gt;5 x 109/L), baseline bone marrow blasts (&le; 50% &amp; &gt; 50%) and prior history of MDS] there was a</p><p>trend in OS benefit in favour of Vidaza. In a few pre-specified subgroups, the OS HR reached</p><p>statistical significance including patients with poor cytogenetic risk, patients with AML with</p><p>myelodysplasia-related changes, patients &lt; 75 years, female patients and white patients.</p><p>&nbsp;</p><p>Haematologic and cytogenetic responses were assessed by the investigator and by the IRC with similar</p><p>results. Overall response rate (complete remission [CR] + complete remission with incomplete blood</p><p>count recovery [CRi]) as determined by the IRC was 27.8% in the Vidaza group and 25.1% in the</p><p>combined CCR group (p = 0.5384). In patients who achieved CR or CRi, the median duration of</p><p>remission was 10.4 months (95% CI = 7.2, 15.2) for the Vidaza subjects and 12.3 months (95%</p><p>CI = 9.0, 17.0) for the CCR subjects. A survival benefit was also demonstrated in patients that had not</p><p>achieved a complete response for Vidaza compared to CCR.</p><p>&nbsp;</p><p>Vidaza treatment improved peripheral blood counts and led to a reduced need for RBC and platelet</p><p>transfusions. A patient was considered RBC or platelet transfusion dependent at baseline if the subject</p><p>had one or more RBC or platelet transfusions during the 56 days (8 weeks) on or prior to</p><p>randomization, respectively. A patient was considered RBC or platelet transfusion independent during</p><p>the treatment period if the subject had no RBC or platelet transfusions during any consecutive 56 days</p><p>during the reporting period, respectively.</p><p>&nbsp;</p><p>Of the patients in the Vidaza group who were RBC transfusion dependent at baseline, 38.5%</p><p>(95% CI = 31.1, 46.2) of these patients became RBC transfusion independent during the treatment</p><p>period, compared with 27.6% of (95% CI = 20.9, 35.1) patients in the combined CCR groups. In</p><p>patients who were RBC transfusion dependent at baseline and achieved transfusion independence on</p><p>treatment, the median duration of RBC transfusion independence was 13.9 months in the Vidaza group</p><p>and was not reached in the CCR group.</p><p>&nbsp;</p><p>Of the patients in the Vidaza group who were platelet transfusion dependent at baseline, 40.6%</p><p>(95% CI = 30.9, 50.8) of these patients became platelet transfusion independent during the treatment</p><p>period, compared with 29.3% of (95% CI = 19.7, 40.4) patients in the combined CCR groups. In</p><p>patients who were platelet transfusion dependent at baseline and achieved transfusion independence on</p><p>treatment, the median duration of platelet transfusion independence was 10.8 months in the Vidaza</p><p>group and 19.2 months in the CCR group.</p><p>Health- Related Quality of Life (HRQoL) was assessed using the European Organization for Research</p><p>and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). HRQoL data could</p><p>be analysed for a subset of the full trial population. While there are limitations in the analysis, the</p><p>available data suggest that patients do not experience meaningful deterioration in quality of life during</p><p>treatment with Vidaza.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following subcutaneous administration of a single 75 mg/m2 dose, azacitidine was rapidly absorbed</p><p>with peak plasma concentrations of 750 &plusmn; 403 ng/mL occurring at 0.5 h after dosing (the first</p><p>sampling point). The absolute bioavailability of azacitidine after subcutaneous relative to intravenous</p><p>administration (single 75 mg/m2 doses) was approximately 89% based on area under the curve (AUC).</p><p>Area under the curve and maximum plasma concentration (Cmax) of subcutaneous admiminstration of</p><p>azacitidine were approximately proportional within the 25 to 100 mg/m2 dose range.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Following intravenous administration, the mean volume of distribution was 76 &plusmn; 26 L, and systemic</p><p>clearance was 147 &plusmn; 47 L/h.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Based on in vitro data, azacitidine metabolism does not appear to be mediated by cytochrome P450</p><p>isoenzymes (CYPs), UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), and</p><p>glutathione transferases (GSTs).</p><p>&nbsp;</p><p>Azacitidine undergoes spontaneous hydrolysis and deamination mediated by cytidine deaminase. In</p><p>human liver S9 fractions, formation of metabolites was independent of NADPH implying that</p><p>azacitidine metabolism was not mediated by cytochrome P450 isoenzymes. An in vitro study of</p><p>azacitidine with cultured human hepatocytes indicates that at concentrations of 1.0 &mu;M to 100 &mu;M (i.e.</p><p>up to approximately 30-fold higher than clinically achievable concentrations), azacitidine does not</p><p>induce CYP 1A2, 2C19, or 3A4 or 3A5. In studies to assess inhibition of a series of P450 isoenzymes</p><p>(CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4) azacitidine up to 100 &mu;M did not produce</p><p>inhibition. Therefore, CYP enzyme induction or inhibition by azacitidine at clinically achievable</p><p>plasma concentrations is unlikely.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Azacitidine is cleared rapidly from plasma with a mean elimination half-life (t&frac12;) after subcutaneous</p><p>administration of 41 &plusmn; 8 minutes. No accumulation occurs after subcutaneous administration of</p><p>75 mg/m2 azacitidine once daily for 7 days. Urinary excretion is the primary route of elimination of</p><p>azacitidine and/or its metabolites. Following intravenous and subcutaneous administration of</p><p>14C-azacitidine, 85 and 50 % of the administered radioactivity was recovered in urine respectively,</p><p>while &lt; 1 % was recovered in faeces.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>The effects of hepatic impairment (see section 4.2), gender, age, or race on the pharmacokinetics of</p><p>azacitidine have not been formally studied.</p><p dir="RTL"><strong>&nbsp;</strong></p><p><u>Renal impairment</u></p><p>Renal impairment has no major effect on the pharmacokinetic exposure of azacitidine after single and</p><p>multiple subcutaneous administrations. Following subcutaneous administration of a single 75 mg/m2</p><p>dose, mean exposure values (AUC and Cmax) from subjects with mild, moderate and severe renal</p><p>impairment were increased by 11-21%, 15-27%, and 41-66%, respectively, compared to normal renal</p><p>function subjects. However, exposure was within the same general range of exposures observed for</p><p>subjects with normal renal function. Azacitidine can be administered to patients with renal impairment</p><p>without initial dose adjustment provided these patients are monitored for toxicity since azacitidine</p><p>and/or its metabolites are primarily excreted by the kidney.</p><p>&nbsp;</p><p><u>Pharmacogenomics</u></p><p>The effect of known cytidine deaminase polymorphisms on azacitidine metabolism has not been</p><p>formally investigated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azacitidine induces both gene mutations and chromosomal aberrations in bacterial and mammalian</p><p>cell systems in vitro. The potential carcinogenicity of azacitidine was evaluated in mice and rats.</p><p>Azacitidine induced tumours of the haematopoietic system in female mice, when administered</p><p>intraperitoneally 3 times per week for 52 weeks. An increased incidence of tumours in the</p><p>lymphoreticular system, lung, mammary gland, and skin was seen in mice treated with azacitidine</p><p>administered intraperitoneally for 50 weeks. A tumorigenicity study in rats revealed an increased</p><p>incidence of testicular tumours.</p><p>&nbsp;</p><p>Early embryotoxicity studies in mice revealed a 44 % frequency of intrauterine embryonal death</p><p>(increased resorption) after a single intraperitoneal injection of azacitidine during organogenesis.</p><p>Developmental abnormalities in the brain have been detected in mice given azacitidine on or before</p><p>closure of the hard palate. In rats, azacitidine caused no adverse reactions when given preimplantation,</p><p>but it was clearly embryotoxic when given during organogenesis. Foetal abnormalities</p><p>during organogenesis in rats included: CNS anomalies (exencephaly/encephalocele), limb anomalies</p><p>(micromelia, club foot, syndactyly, oligodactyly) and others (microphthalmia, micrognathia,</p><p>gastroschisis, oedema, and rib abnormalities).</p><p>&nbsp;</p><p>Administration of azacitidine to male mice prior to mating with untreated female mice resulted in</p><p>decreased fertility and loss of offspring during subsequent embryonic and postnatal development.</p><p>Treatment of male rats resulted in decreased weight of the testes and epididymides, decreased sperm</p><p>counts, decreased pregnancy rates, an increase in abnormal embryos and increased loss of embryos in</p><p>mated females (see section 4.4).</p><p dir="RTL"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol, Acetonitrile HP, Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.2 Incompatibilities</strong></p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened powder vial:
2 years
After reconstitution:
After reconstitution:
When Vidaza is reconstituted using water for injections that has not been refrigerated, chemical and
physical in-use stability of the reconstituted medicinal product has been demonstrated at 25 °C for
45 minutes and at 2 °C to 8 °C for 8 hours.
The shelf life of the reconstituted medicinal product can be extended by reconstituting with
refrigerated (2 °C to 8 °C) water for injections. When Vidaza is reconstituted using refrigerated (2 °C
to 8 °C) water for injections, the chemical and physical in-use stability of the reconstituted medicinal
product has been demonstrated at 2 °C to 8 °C for 22 hours.
From a microbiological point of view, the reconstituted product should be used immediately. If not
used immediately, in-use storage times and conditions prior to use are the responsibility of the user
and must not be longer than 8 hours at 2 °C to 8 °C when reconstituted using water for injections that
has not been refrigerated or not longer than 22 hours when reconstituted using refrigerated (2 °C to
8 °C) water for injections.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.4 Special precautions for storage</strong></p><p><u>Unopened vials</u></p><p>Do not store above 30C</p><p><u>Reconstituted suspension</u></p><p>For storage conditions after reconstitution of the medicinal product, see section 6.2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>USP type-1 clear molded glass vial</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Recommendations for safe handling</u></p><p>Azacitidine is a cytotoxic medicinal product and, as with other potentially toxic compounds,</p><p>caution should be exercised when handling and preparing azacitidine suspensions. Procedures for</p><p>proper handling and disposal of anticancer medicinal products should be applied.</p><p>If reconstituted azacitidine comes into contact with the skin, immediately and thoroughly wash</p><p>with soap and water. If it comes into contact with mucous membranes, flush thoroughly with</p><p>water.</p><p>&nbsp;</p><p><u>Reconstitution procedure</u></p><p>Vidaza should be reconstituted with water for injections. The shelf life of the reconstituted medicinal</p><p>product can be extended by reconstituting with refrigerated (2 &deg;C to 8 &deg;C) water for injections. Details</p><p>on storage of the reconstituted product are provided below.</p><p>1. The following supplies should be assembled:</p><p>Vial (s) of azacitidine; vial(s) of water for injections; non-sterile surgical gloves; alcohol wipes;</p><p>5 mL injection syringe(s) with needle(s).</p><p>2. 4 mL of water for injections should be drawn into the syringe, making sure to purge any air</p><p>trapped within the syringe.</p><p>3. The needle of the syringe containing the 4 mL of water for injections should be inserted through</p><p>the rubber top of the azacitidine vial followed by injection of the water for injections into</p><p>the vial.</p><p>4. Following removal of the syringe and needle, the vial should be vigorously shaken until a</p><p>uniform cloudy suspension is achieved. After reconstitution each mL of suspension will contain</p><p>25 mg of azacitidine (100 mg/4 mL). The reconstituted product is a homogeneous, cloudy</p><p>suspension, free of agglomerates. The product should be discarded if it contains large particles</p><p>or agglomerates. Do not filter the suspension after reconstitution since this could remove the</p><p>active substance. It must be taken into account that filters are present in some adaptors, spikes</p><p>and closed systems; therefore such systems should not be used for administration of the</p><p>medicinal product after reconstitution.</p><p>5. The rubber top should be cleaned and a new syringe with needle inserted into the vial. The vial</p><p>should then be turned upside down, making sure the needle tip is below the level of the liquid.</p><p>The plunger should then be pulled back to withdraw the amount of medicinal product required</p><p>for the proper dose, making sure to purge any air trapped within the syringe. The syringe with</p><p>needle should then be removed from the vial and the needle disposed of.</p><p>6. A fresh subcutaneous needle (recommended 25-gauge) should then be firmly attached to the</p><p>syringe. The needle should not be purged prior to injection, in order to reduce the incidence of</p><p>local injection site reactions.</p><p>7. When more than 1 vial is needed all the above steps for preparation of the suspension should be</p><p>repeated. For doses requiring more than 1 vial, the dose should be equally divided e.g., dose</p><p>150 mg = 6 mL, 2 syringes with 3 mL in each syringe. Due to retention in the vial and needle, it</p><p>may not be feasible to withdraw all of the suspension from the vial.</p><p>8. The contents of the dosing syringe must be re-suspended immediately prior to administration.</p><p>The syringe filled with reconstituted suspension should be allowed up to 30 minutes prior to</p><p>administration to reach a temperature of approximately 20 &deg;C-25 &deg;C. If the elapsed time is</p><p>longer than 30 minutes, the suspension should be discarded appropriately and a new dose</p><p>prepared. To re-suspend, vigorously roll the syringe between the palms until a uniform, cloudy</p><p>suspension is achieved. The product should be discarded if it contains large particles or</p><p>agglomerates.</p><p><u>Storage of the reconstituted product</u></p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p><p><u>Calculation of an individual dose</u></p><p>The total dose, according to the body surface area (BSA) can be calculated as follows:</p><p>Total dose (mg) = Dose (mg/m2) x BSA (m2)</p><p>The following table is provided only as an example of how to calculate individual azacitidine doses</p><p>based on an average BSA value of 1.8 m2.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Reconstituted Vidaza should be injected subcutaneously (insert the needle at a 45-90o angle) using a</p><p>25-gauge needle into the upper arm, thigh or abdomen.</p><p>Doses greater than 4 mL should be injected into two separate sites.</p><p>Injection sites should be rotated. New injections should be given at least 2.5 cm from the previous site</p><p>and never into areas where the site is tender, bruised, red, or hardened.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local</p><p>requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi
Riyadh, Kingdome Saudi Arabia
medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sep,2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>